SAT 3247
Alternative Names: SAT-3247Latest Information Update: 26 Sep 2025
At a glance
- Originator Satellos Bioscience
- Class Small molecules
- Mechanism of Action Adaptor-associated kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Duchenne muscular dystrophy
- Preclinical Facioscapulohumeral muscular dystrophy; Muscle injury
Most Recent Events
- 22 Sep 2025 Satellos Biosciences files an IND application with the USFDA, MHRA, Medicines and Medical Devices Agency of Serbia, EMA, and TGA in Duchenne muscular dystrophy
- 22 Sep 2025 Satellos initiates a phase Ib extension trial in Duchenne muscular dystrophy in Australia
- 14 Aug 2025 Adverse event data from phase Ib trial in Duchenne muscular dystrophy released by Satellos Bioscience